Police & Firemen s Retirement System of New Jersey Has $2.72 Million Position in Medpace Holdings, Inc. $MEDP

Police & Firemen s Retirement System of New Jersey lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,665 shares of the company’s stock after selling 537 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Medpace were worth $2,720,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in MEDP. Mawer Investment Management Ltd. acquired a new position in shares of Medpace in the 1st quarter worth approximately $212,131,000. Vulcan Value Partners LLC grew its position in Medpace by 221.6% in the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock valued at $99,159,000 after acquiring an additional 224,578 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in Medpace by 675.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock worth $37,009,000 after acquiring an additional 105,807 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock valued at $361,596,000 after acquiring an additional 102,015 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Medpace by 36.0% in the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock valued at $102,830,000 after purchasing an additional 89,347 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Robert O. Kraft sold 6,472 shares of the firm’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $591.85, for a total value of $3,830,453.20. Following the transaction, the director owned 833 shares of the company’s stock, valued at approximately $493,011.05. This trade represents a 88.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Susan E. Burwig sold 18,000 shares of Medpace stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $605.00, for a total transaction of $10,890,000.00. Following the sale, the vice president directly owned 47,500 shares of the company’s stock, valued at $28,737,500. This represents a 27.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 170,255 shares of company stock valued at $96,157,774 over the last 90 days. Corporate insiders own 20.30% of the company’s stock.

Medpace Price Performance

MEDP opened at $590.18 on Wednesday. The stock has a market capitalization of $16.62 billion, a P/E ratio of 41.27, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. The company’s 50 day simple moving average is $543.35 and its 200-day simple moving average is $428.47. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $625.00.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Jefferies Financial Group raised their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a report on Tuesday, September 9th. William Blair reissued a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. TD Cowen increased their price target on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Finally, Cowen reiterated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $487.18.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.